Immune Checkpoint Blockade and Beyond: Next-Generation Cancer Immunotherapies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 July 2026 | Viewed by 41
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, immune checkpoint blockade (ICB) has transformed the landscape of cancer therapy, providing durable responses and long-term survival benefits for a subset of patients across multiple malignancies. However, the clinical success of current immune checkpoint inhibitors remains limited by resistance mechanisms, immune-related adverse events, and variable tumor microenvironmental contexts. To address these challenges, next-generation cancer immunotherapies are being developed, integrating molecular insights, novel targets, and multimodal strategies that expand beyond classical checkpoint pathways such as PD-1/PD-L1 and CTLA-4.
This Special Issue, “Immune Checkpoint Blockade and Beyond: Next-Generation Cancer Immunotherapies,” aims to highlight cutting-edge research on the molecular mechanisms, predictive biomarkers, and translational strategies that advance our understanding and application of immunotherapy. We welcome original research and comprehensive reviews on emerging immune modulators, combinatorial immunotherapy approaches, immune metabolism, tumor microenvironmental remodeling, and novel delivery platforms that enhance anti-tumor immunity. By bringing together studies from basic, translational, and clinical perspectives, this Special Issue seeks to foster interdisciplinary collaboration and accelerate the development of more effective and personalized cancer immunotherapies.
Dr. Wenxuan Zhang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint blockade
- cancer immunotherapy
- tumor microenvironment
- immune resistance
- PD-1/PD-L1
- CTLA-4
- combinatorial therapy
- immunometabolism
- biomarkers
- translational oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
